

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6790178

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
IZUN PHARMACEUTICALS CORPORATION	06/10/2021
RECEIVING PARTY DATA	
Name:	JONATHAN KALMAN
Street Address:	42/6 DERECH
City:	BETHLEHEM JERUSALEM
State/Country:	ISRAEL
Postal Code:	93350405
PROPERTY NUMBERS Total: 13	
Property Type	Number
Patent Number:	7563466
Patent Number:	8075926
Patent Number:	9855307
Patent Number:	7985430
Patent Number:	7285295
Patent Number:	8021696
Patent Number:	8747914
Patent Number:	8075924
Patent Number:	8383170
Patent Number:	8852652
Patent Number:	8771759
Patent Number:	9314491
Patent Number:	10293010
CORRESPONDENCE DATA	
Fax Number:	(800)692-4850
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9549894150
Email:	robert.goldfarbpa@gmail.com
Correspondent Name:	ROBERT I. GOLDFARB
Address Line 1:	6100 HOLLYWOOD BOULEVARD

PATENT

Address Line 2:	207
Address Line 4:	HOLLYWOOD, FLORIDA 33024

ATTORNEY DOCKET NUMBER:	IZUN2021
-------------------------	----------

NAME OF SUBMITTER:	ROBERT I GOLDFARB
--------------------	-------------------

SIGNATURE:	/s/ Robert I Goldfarb
------------	-----------------------

DATE SIGNED:	06/30/2021
--------------	------------

	This document serves as an Oath/Declaration (37 CFR 1.63).
--	--

Total Attachments: 6

source=5 - Patent Security - Final Executed#page1.tif
source=5 - Patent Security - Final Executed#page2.tif
source=5 - Patent Security - Final Executed#page3.tif
source=5 - Patent Security - Final Executed#page4.tif
source=5 - Patent Security - Final Executed#page5.tif
source=5 - Patent Security - Final Executed#page6.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (the "Agreement"), is made this 10th day of June, 2021, by and between Izun Pharmaceuticals Corporation ("Debtor") and Jonathan Kalman ("Secured Party"), as collateral agent for the Note Holders pursuant to the Security Agreement dated as of June 10th 2021, between the Debtor and the Secured Party, (as from time to time amended, modified, supplemented or restated, the "Security Agreement"). Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Security Agreement.

WHEREAS, the Debtor has, pursuant to the Security Agreement, granted to the Secured Party a security interest in and to all of the right, title and interest of the Debtor, in, to and under the Collateral as security for the payment and performance in full when due of the Obligations; and


WHEREAS, the Debtor and the Secured Party wish to further memorialize the security interest described above as it relates to the patents identified in Exhibit 1, attached hereto, and incorporated herein by this reference (the "Patents") and to perfect the security interest of the Secured Party in the Patents shall electronically file this Agreement in the appropriate United States Patent and Trademark Office and Canadian Intellectual Property Office, respectively.

NOW THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Debtor hereby grants unto the Secured Party a security interest in and lien on all of its right, title and interest in the Patents, as collateral security for the payment and performance in full when due of the Obligations. The Debtor hereby acknowledges and affirms that the rights and remedies of the Secured Party with respect to the security interest in the Patents made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

[signatures on next page]

IN WITNESS WHEREOF, the parties have signed this Patent Security Agreement as of
the day and year first written above.

DEBTOR
Izun Pharmaceuticals Corporation

By: 
Name: Dr. William Levine

Title: CEO

SECURED PARTY


Jonathan Kalman

EXHIBIT I
to
PATENT SECURITY AGREEMENT
Patents

Izun Pharmaceuticals IP Summary Table

Priority Date	Expiration	Granted	Pending	Patent Summary	Products
<i>Family 1: Herbal compositions for the treatment of mucosal lesions</i>					
2001-05-23	2022-05-22	US 7,563,466 US 8,075,926 US 9,855,307 EP 1395271B IL 158947 JP 4465155 CA 2447180		Relates to compositions comprising the active herbs Echinacea purpurea, Sambucus nigra and Centella asiatica. The compositions can be used for treating mucosal lesions of the oral, anal or vaginal mucosa and surrounding tissues, and skin lesions.	Periopatch, Mouth Rinse, Soothe and Cure, Izun Grip Strip, Hydrogel, Oral Mucositis Product, Potential Ulcerative Colitis Product, Wound care, Acne and other topical indications, Potential products for the anal and vaginal mucosa.
<i>Family 2: Solid mucoadhesive composition</i>					
2002-11-27	2023-03-03	US 7,985,430 EP 1569625B CA 2506034		Relates to solid adhesive compositions and muco-adhesive compositions comprising active herbs, an adhesive polymer and polyvinylpyrrolidone.	Potential mucoadhesive products for buccal/ vaginal/ anal administration (US), or other topical adhesive applications
<i>Family 3: Transmucosal oral delivery device</i>					
2004-11-22	2025-11-21	US 7,285,295 EP 1814564B AU 2005309652 JP 5096921 IL 182999 CA2587565 HK 081015307		Relates to formulations for transmucosal delivery comprising a backing layer and an adhesive reservoir containing a plant extract, and methods of treatment using said formulations.	Periopatch and applications of mucosal delivery
<i>Family 4: Anti-inflammatory dissolvable film</i>					

2006-06-20	2027-06-20	US US EP AU AU CA IL JP JP	8,021,696 8,747,914 2046359 2007261013 2013242845 2658337 196032 5820493 5992594		Relates to a multi-layered dissolvable film formulation, comprising herbal bioactive agent(s) and polymer(s), for the treatment of mucosal or adjacent tissue.	Soothe and Cure and other potential products for the anal/ vaginal mucosa.
<i>Family 5: Film delivering rinse</i>						
2006-07-20	2027-07-20	US US US EP EP CA AU JP IL KR KR	8,075,924 8,383,170 8,852,652 2068900B 2594278B 2660894 2007275217 5513111 196521 10-1474809 10-1531185		Relates to liquid and rinse formulations, as well as a film, patch or adhesive solid formulations, comprising herbal extracts and an antimicrobially effective amount of a surfactant. This family also relates to methods of treating of mucosal or adjacent tissue, by using said formulations.	Oral liquid and rinse products, products for the anal, vaginal or mucosal indications or adjacent tissues.
<i>Family 6: Topical anti-inflammatory combination</i>						
2008-07-22	2039-07-15	US US JP EP EP IL IL CA KR KR CA	8,771,759 9,314,491 5707655 2320920B 2937093B 210820 243546 2731445 10-1660246 10-2016-7025128 3000397		Relates to a method of treating a non-mucosal topical tissue, including non-mucosal wound, by using composition comprising herbal extract(s) and an effective amount of a quaternary ammonium surfactant.	Products for non-mucosal indications, including acne, wounds, eczema and others.
<i>Family 7: Novel methods and compositions for treatment of disease</i>						

2012-03-14	2033-03-13	AU 2013233943 ZL 201380014283.9 JP 6410355 RU 2683774 KR 10-2168118	US 17/128,118 US 2015/0064291 EP 2825185 CA 2867260 IN 8440/DELNP/2014 IL 234606- accepted BR 112014022694-6- allowed	This family relates to improved extraction process with higher potency than previously identified herbal extracts, and methods of making the extracts.	All products.
<i>Family 8: Methods for treatment of m-tox inhibitor-associated stomatitis</i>					
2013-10-14	2034-10-13	US 10,293,010 IL 245100	CA 2927559	This family relates to methods for prevention or treatment of mIAS by administering a composition comprising extracts of the plant species Sambucus nigra, Echinacea purpurea, and Centella asiatica.	
<i>Family 15: Hydrogel Wound Treatment</i>					
2018-11-04	2039-11-04	IL 262744	PCT/IL2019/051203	This patent family relates to compositions for treating wounds and methods for treatment using the compositions.	
<i>Family 17: Treatment of oral mucositis</i>					
2020-10-28	2041-10-28		US Provisional application	This patent family relates to methods for treatment of oral mucositis with a composition comprising extracts from the plant species Sambucus nigra, Echinacea purpurea, and Centella asiatica.	